Sunday, February 1

Healthcare

BioCardia shares climb as it gets FDA clearance for its Morph DNA product family

08/30/20241 Min Read

BioCardia clearance climb DNA family FDA Morph product shares

Previous ArticleNuvectis gains on FDA’s orphan drug designation for cancer therapy

Next Article American Diversified to cancel 142M shares